Navigation Links
Researchers unfold the mechanisms underlying blood disorders
Date:7/24/2012

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment. The work was carried out with funding from the Academy of Finland, the Cancer Society of Finland, National Institutes of Health and the Sigrid Juslius Foundation.

Blood cell formation and activity is regulated by cytokines, small cell-signalling protein molecules, through a signal pathway mediated by Janus kinases (JAKs), a family of enzymes. Previous studies have shown that mutations in JAKs can cause severe haematological disorders as well as immunological diseases. These mutations are concentrated in the pseudokinase domain.

Leading laboratories and pharmaceutical companies around the world have long aimed at defining the structure of the pseudokinase domain of JAKs, as it has been found to be a veritable hotspot for pathogenic mutations causing haematological disorders. Led by Professor Olli Silvennoinen, the Finnish research team has now successfully determined the three-dimensional atomic-level structure of both the normal and the pathogenic pseudokinase domain.

Novel therapeutics

Professor Silvennoinen's team is the first to describe the structure of the pseudokinase domain of JAKs, laying bare the domain's enzymatic mechanisms at the atomic level. The team also managed to determine the structural change, caused by the JAK2 V617F mutation, which gives rise to common myeloproliferative diseases (MPDs), such as polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). PV and ET are blood disorders characterised by an overproduction of red blood cells or platelets, whereas MF is a disorder that causes scar tissue to accumulate in the bone marrow. The team's research results can be put to good use in developing new, targeted therapeutics for these disorders.

The study now published in Nature Structural & Molecular Biology builds on the long-standing expertise of Professor Silvennoinen's team in Janus kinases. In the early 1990s, while working in the US, Silvennoinen successfully cloned the JAK2 gene and demonstrated its activity in the signalling pathways of erythropoietin and interferon. In Finland, the Silvennoinen's work focused on the pseudokinase domain, determining and characterising its regulatory function.


'/>"/>
Contact: Professor Olli Silvennoinen
olli.silvennoinen@uta.fi
358-503-595-740
Academy of Finland
Source:Eurekalert

Related medicine news :

1. New lipid screening guidelines for children overly aggressive, UCSF researchers say
2. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
3. UGA researchers develop rapid diagnostic test for pathogens, contaminants
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
6. Researchers to use novel metabolomics technology for COPD
7. Researchers hit back at early bodycheck theory
8. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
9. Researchers developing new multiple sclerosis drug that can be taken orally
10. UMass Amherst researchers unravel secrets of parasites replication
11. U-M researchers identify new genetic cause for chronic kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: